Lipid Nanoparticles and Exosomes—Characterize Subvisible Particles with Confidence

Gain crystal-clear insight into the stability of your therapies. With our high throughput, low volume technology, you can achieve LNP and exosome characterization with confidence—from early stage inception through product release.

Get the Stability You Need

LNP_Page_Img (1)

Why Use Aura for LNP Characterization and Exosome Characterization?

Because you can achieve so much more insight with much less material:
  • Analyze product stability and aggregation analysis
  • Identify SYBR™-labeled nucleic acid aggregates from unstable products
  • Detect and quantify particles not measured by DLS or SEC
  • Determine root cause for unstable gene therapies
  • Recommended method by FDA (USP 788 Compendial Method 2)
  • Achieve more accurate results with minimal amounts of sample (as little as 5 μL per test)
  • Gather comprehensive data and insight into aggregate particles – size, morphology, counts, distribution
  • Get insights quickly with rapid analysis time of 1 minute per sample
  • Benefit from a wide working range: measure particles from 1 μm to 5 mm with high reproducibility
  • Analyze particles without the interference of buffer or matrix for higher sensitivity
  • 21 CFR Part 11 software available

Overcome the Challenge of Predicting Quality and Stability of LNPs

A Smarter and Faster Exosome Characterization Method

Exosome characterization with Aura GT simplifies and expedites the process of selecting the most suitable candidate for development. Much like AAV and LNP therapies, exosomes can aggregate and contain nucleic acids.

Thanks to small sample volumes, stability assessment can occur during earlier development stages, allowing for more informed decisions to be made. This saves valuable time and resources before investing in an unsuitable path that may turn out to be costly and inefficient.